drugset
drugset / Trial / NCT00928551

Comparative Formulation Study of Vabicaserin

NCT00928551 ↗

Phase 1 Completed 15 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

This study will compare two different formulations of vabicaserin.

Timeline

Start
2009-06
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject vabicaserin Small molecule — —

Indications

No indication recorded.